The FDA placed a partial hold on the VELA study of BLU-222 due to some patients experiencing visual toxicity, but the company anticipates reporting data and said it is near identifying Phase II dose.

The biopharma industry may not have been the fastest adopter of artificial intelligence, but its vast potential means companies of every shape and size know they cannot ignore it. Executives, advisors and investors share their predictions around the impact of AI in 2023.

Fresh out of an impressive new round of financing and armed with $32m, Shanghai's Degron Therapeutics is aiming for nothing but first-in-class treatments. Its co-founder and CSO shares views on creating original innovative drugs from inside China in an exclusive interview with Scrip.

The Massachusetts-based biotech’s fundraise will be used to discover and develop molecular glues with an initial focus on cancer targets.